{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:24:41Z","timestamp":1759335881314},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clinthera.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T08:53:57Z","timestamp":1536310437000},"page":"1711-1719.e1","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States"],"prefix":"10.1016","volume":"40","author":[{"given":"Xinke","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krutika","family":"Jariwala-Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Romanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.08.005_bib0002","series-title":"Acute Leukemias","first-page":"77","article-title":"Acute lymphoblastic leukemia: epidemiology and etiology","author":"Wartenberg","year":"2008"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0006","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2017.35.15_suppl.7008","article-title":"Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0007","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0008","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0009","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0011","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0014","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0017","first-page":"130","article-title":"Manifestations and management of veno-occlusive disease\/sinusoidal obstruction syndrome in the era of contemporary therapies","volume":"15","author":"Tewari","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0018","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0019","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00277-015-2486-9","article-title":"Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)","volume":"94","author":"de Witte","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/2040620712441943","article-title":"Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease","volume":"3","author":"Richardson","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0022","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40261-014-0242-x","article-title":"Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation","volume":"34","author":"Keating","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11531840-000000000-00000","article-title":"Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies","volume":"12","author":"Cefalo","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0025","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bbmt.2017.03.008","article-title":"Defibrotide for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome: interim results from a treatment IND study","volume":"23","author":"Richardson","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0026","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0027","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0028","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood.V126.23.4452.4452","article-title":"Hospital cost associated with veno-occlusive disease (VOD) in patients with hematopoietic stem cell transplant (HSCT)","volume":"126","author":"Dvorak","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2018.08.005_bib0030","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V126.23.3273.3273","article-title":"A Model estimating indirect costs of premature death associated with severe hepatic veno-occlusive disease (sVOD) among hematopoietic stem cell transplant (HSCT) patients in the United States (U.S.)","volume":"126","author":"Quock","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T22:13:15Z","timestamp":1571868795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818303655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0149291818303655"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Amgen Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}